Alpha Tau Medical targets major 2026 catalysts as Alpha DaRT gains momentum; key pancreatic & GBM readouts ahead. Read the full analysis here of DRTS stock.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...

JERUSALEM, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® ...

Alpha Tau Medical Ltd. announced significant advancements in their alpha-radiation cancer treatment, Alpha DaRT®, during the 2025 ASCO GI Symposium and R&D Update Day. Interim results from three ...

Alpha particle radioluminescence detection and imaging is an advanced optical technique that capitalises on the light emitted when alpha particles interact with air molecules. When alpha particles – ...

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...

Alpha Tau Medical Ltd. announced that it has achieved Medical Device Single Audit Program (MDSAP) certification for its manufacturing facility in Jerusalem, which is a key step in ensuring quality, ...

CLEVELAND, Ohio — The Ohio State University’s James Cancer Hospital has treated the world’s first brain cancer patient to receive a new radiation technology that attacks tumors from within, the ...

A new approach to treating the most malignant type of brain cancer -- glioblastoma -- has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates ...